Impact of Variant Histology on Clinical and Pathological Outcomes in Patients with the Upper Urinary Tract Urothelial Carcinoma.
Survival analysis
upper system transitional epithelial cell carcinoma
variant histology
Journal
Sisli Etfal Hastanesi tip bulteni
ISSN: 1302-7123
Titre abrégé: Sisli Etfal Hastan Tip Bul
Pays: Turkey
ID NLM: 9424130
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
06
2021
accepted:
30
07
2021
entrez:
22
8
2022
pubmed:
23
8
2022
medline:
23
8
2022
Statut:
epublish
Résumé
The objective of the study was to determine the effect of variant histology on pathological outcomes and survival in patients operated for the upper urinary tract urothelial carcinoma (UTUC). Data of 128 patients who were operated for UTUC between 2001 and 2019 were retrospectively analyzed. Patients with pure urothelial carcinoma and patients with variant histology were compared in terms of demographics, pathological outcomes, and survival. The mean age of the patients was 65±11 years, female to male ratio was 30/98 and median follow-up period was 26.5 (1-176) months. Variant histology was detected in 14.8% of patients. Variant histology was found to be associated with surgical margin positivity, lymph node metastasis, presence of lymphovascular invasion, high tumor stage and grade (p=0.001, p=0.012, p=0.001, p=0.002, and p=0.009, respectively). Three-year cancer-specific and overall survival rates were 79.6% and 77.3%, respectively. There was no statistically significant relationship between variant histology with cancer-specific and overall survival (p=0.514 and p=0.515, respectively). Variant histology of UTUC was found to be associated with locally advanced disease, but its effect on survival could not be demonstrated.
Identifiants
pubmed: 35990296
doi: 10.14744/SEMB.2021.23427
pii: SEMB-56-284
pmc: PMC9350051
doi:
Types de publication
Journal Article
Langues
eng
Pagination
284-290Informations de copyright
© Copyright 2022 by The Medical Bulletin of Sisli Etfal Hospital.
Déclaration de conflit d'intérêts
None declared.
Références
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
World J Urol. 2017 Mar;35(3):379-387
pubmed: 27604375
J Urol. 2020 Jun;203(6):1075-1084
pubmed: 31479406
Urol Oncol. 2015 Jan;33(1):18.e15-18.e20
pubmed: 25459358
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
J Urol. 2012 Aug;188(2):398-404
pubmed: 22698626
Int J Clin Oncol. 2015 Apr;20(2):362-8
pubmed: 24964974
BJU Int. 2019 Nov;124(5):738-745
pubmed: 30908835
BJU Int. 2013 Aug;112(4):453-61
pubmed: 23464979
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur Urol. 2010 Oct;58(4):581-7
pubmed: 20619530
Clin Genitourin Cancer. 2019 Jun;17(3):e394-e407
pubmed: 30782419
World J Urol. 2016 Jun;34(6):871-7
pubmed: 26497969
Urol Oncol. 2013 Nov;31(8):1650-5
pubmed: 22608543
Urol Oncol. 2017 Jul;35(7):458.e9-458.e15
pubmed: 28347659
Semin Hematol. 2015 Oct;52(4):261-9
pubmed: 26404438